Federal Register / Vol. 75, No. 41 / Wednesday, March 3, 2010 / Notices 9615 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 16, 2009, and 

published in the Federal Register on 

October 28, 2009, (74 FR 55587), 

American Radiolabeled Chemical, Inc., 

101 Arc Drive, St. Louis, Missouri 

63146, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010) ........................................ I 

Ibogaine (7260) ............................ I 

Lysergic acid diethylamide (7315) I 

Tetrahydrocannabinols (7370) ...... I 

Dimethyltryptamine (7435) ........... I 

1-[1-(2– 

Thienyl)cyclohexyl]piperidine 

(7470) ........................................ I 

Dihydromorphine (9145) ............... I 

Normorphine (9313) ..................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Amobarbital (2125) ....................... II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Metazocine (9240) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273) ............... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) .................... II 

Phenazocine (9715) ..................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

small quantities of the listed controlled 

substances as radiolabeled compounds 

for biochemical research. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

American Radiolabeled Chemical, Inc. 

to manufacture the listed basic classes 

of controlled substances is consistent 

with the public interest at this time. 

DEA has investigated American 

Radiolabeled Chemical Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: February 24, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–4403 Filed 3–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances Notice of Registration 

By Notice dated October 21, 2009, and 

published in the Federal Register on 

October 28, 2009, (74 FR 55588), 

Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066–1742, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the basic classes 

of controlled substances listed in 

schedules I and II: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010) ........................................ I 

Tetrahydrocannabinols (7370) ...... I 

Dihydromorphine (9145) ............... I 

Difenoxin (9168) ........................... I 

Propiram (9649) ............................ I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) .................... II 

Noroxymorphone (9668) ............... II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Johnson Matthey Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: February 24, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–4404 Filed 3–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Office of the Secretary 

Bureau of International Labor Affairs: 

Labor Advisory Committee for Trade 

Negotiations and Trade Policy 

ACTION: Meeting Notice. 

SUMMARY: Pursuant to the provisions of 

the Federal Advisory Committee Act 

(Pub. L. 92–463, as amended), notice is 

hereby given of a meeting of the Labor 

Advisory Committee for Trade 

Negotiation and Trade Policy. 

Date, Time, Place: March 16, 2010; 

10:30 a.m.–11:30 a.m.; U.S. Department 

of Labor, Secretary’s Conference Room, 

200 Constitution Ave., NW., 

Washington, DC. 

Purpose: The meeting will include a 

review and discussion of current issues 

which influence U.S. trade policy. 

Potential U.S. negotiating objectives and 

bargaining positions in current and 

anticipated trade negotiations will be 

discussed. Pursuant to 19 U.S.C. 2155(f) 

it has been determined that the meeting 

will be concerned with matters the 

disclosure of which would seriously 

compromise the Government’s 

negotiating objectives or bargaining 

mstockstill on DSKH9S0YB1PROD with NOTICES

9616 Federal Register / Vol. 75, No. 41 / Wednesday, March 3, 2010 / Notices 

positions. Accordingly, the meeting will 

be closed to the public. 

FOR FURTHER INFORMATION CONTACT: 

Gregory Schoepfle, Director, Office of 

Trade and Labor Affairs; Phone: (202) 

693–4887. 

Signed at Washington, DC, the 25th day of 

February 2010. 

Sandra Polaski, 

Deputy Undersecretary, International Affairs. 

[FR Doc. 2010–4352 Filed 3–2–10; 8:45 am] 

BILLING CODE 4510–28–P 

NATIONAL SCIENCE FOUNDATION 

Committee Management Renewals 

The NSF management officials having 

responsibility for three advisory 

committees listed below have 

determined that renewing these groups 

for another two years is necessary and 

in the public interest in connection with 

the performance of duties imposed upon 

the Director, National Science 

Foundation (NSF), by 42 U.S.C. 1861 et 

seq. This determination follows 

consultation with the Committee 

Management Secretariat, General 

Services Administration. 

Committees: 

Advisory Committee for Environmental 

Research and Education, #9487. 

Proposal Review Panel for Industrial 

Innovations and Partnerships, #28164. 

Proposal Review Panel for Emerging 

Frontiers in Research and Innovation, 

#34558. 

Effective date for renewal is March 1, 

2010. For more information, please 

contact Susanne Bolton, NSF, at (703) 

292–7488. 

Susanne Bolton, 

Committee Management Officer. 

[FR Doc. 2010–4233 Filed 3–2–10; 8:45 am] 

BILLING CODE 7555–01–P 

NUCLEAR REGULATORY 

COMMISSION 

[Docket Nos. 50–266 and 50–301; NRC– 

2010–0078] 

FPL Energy Point Beach, LLC; Notice 

of Consideration of Issuance of 

Amendment to Facility Operating 

License, Proposed No Significant 

Hazards Consideration Determination, 

and Opportunity for a Hearing 

The U.S. Nuclear Regulatory 

Commission (the Commission) is 

considering issuance of an amendment 

to Renewed Facility Operating License 

Nos. DPR–24 and DPR–27 issued to FPL 

Energy Point Beach, LLC (the licensee) 

for operation of the Point Beach Nuclear 

Plant, Units 1 and 2 located in the Town 

of Two Creeks, Manitowoc County, 

Wisconsin. 

On July 14, 2009, the Nuclear 

Regulatory Commission published a 

Notice of Consideration of Issuance, 

Proposed No Significant Hazards 

Consideration Determination, and 

Opportunity for Hearing in the Federal 

Register (74 FR 34048) for a proposed 

amendment that would change the legal 

name of the licensee and owner from 

‘‘FPL Energy Point Beach, LLC’’ to 

‘‘NextEra Energy Point Beach, LLC.’’ 

On January 19, 2010, the licensee 

submitted a supplement which 

expanded the original scope of work. 

The proposed revisions would correct 

an administrative error within a License 

Condition contained in Appendix C of 

the Renewed Facility Operating 

Licenses. The correction changes ‘‘FPLE 

Group Capital’’ to the appropriately 

titled ‘‘FPL Group Capital.’’ 

Before issuance of the proposed 

license amendment, the Commission 

will have made findings required by the 

Atomic Energy Act of 1954, as amended 

(the Act), and the Commission’s 

regulations. 

The Commission has made a 

proposed determination that the 

amendment request involves no 

significant hazards consideration. Under 

the Commission’s regulations in Title 10 

of the Code of Federal Regulations (10 

CFR), Section 50.92, this means that 

operation of the facility in accordance 

with the proposed amendment would 

not (1) involve a significant increase in 

the probability or consequences of an 

accident previously evaluated; or (2) 

create the possibility of a new or 

different kind of accident from any 

accident previously evaluated; or (3) 

involve a significant reduction in a 

margin of safety. As required by 10 CFR 

50.91(a), the licensee has provided its 

analysis of the issue of no significant 

hazards consideration, which is 

presented below: 

1. Does the proposed amendment involve 

a significant increase in the probability or 

consequences of an accident previously 

evaluated? 

Response: No. 

This request is for administrative changes 

only. No actual facility equipment or 

accident analyses will be affected by the 

proposed changes. Therefore, this request 

will have no impact on the probability or 

consequences of an accident previously 

evaluated. 

2. Does the proposed amendment create 

the possibility of a new or different kind of 

accident from any accident previously 

evaluated? 

Response: No. 

This request is for administrative changes 

only. No actual facility equipment or 

accident analyses will be affected by the 

proposed changes and no failure modes not 

bounded by previously evaluated accidents 

will be created. Therefore, this request will 

not create the possibility of a new or different 

kind of accident from any accident 

previously evaluated. 

3. Does the proposed amendment involve 

a significant reduction in a margin of safety? 

Response: No. 

Margin of safety is associated with 

confidence in the ability of the fission 

product barriers (i.e., fuel cladding, reactor 

coolant system pressure boundary, and 

containment structure) to limit the level of 

radiation dose to the public. This request is 

for administrative changes only. No actual 

plant equipment or accident analyses will be 

affected by the proposed changes. 

Additionally, the proposed changes will not 

relax any criteria used to establish safety 

limits, will not relax any safety system 

settings, and will not relax the bases for any 

limiting conditions of operation. Therefore, 

these proposed changes will not involve a 

significant reduction in a margin of safety. 

The NRC staff has reviewed the 

licensee’s analysis and, based on this 

review, it appears that the three 

standards of 10 CFR 50.92(c) are 

satisfied. Therefore, the NRC staff 

proposes to determine that the 

amendment request involves no 

significant hazards consideration. 

The Commission is seeking public 

comments on this proposed 

determination. Any comments received 

within 30 days after the date of 

publication of this notice will be 

considered in making any final 

determination. 

Normally, the Commission will not 

issue the amendment until the 

expiration of 60 days after the date of 

publication of this notice. The 

Commission may issue the license 

amendment before expiration of the 60- 

day period provided that its final 

determination is that the amendment 

involves no significant hazards 

consideration. In addition, the 

Commission may issue the amendment 

prior to the expiration of the 30-day 

comment period should circumstances 

change during the 30-day comment 

period such that failure to act in a 

timely way would result, for example, 

in derating or shutdown of the facility. 

Should the Commission take action 

prior to the expiration of either the 

comment period or the notice period, it 

will publish in the Federal Register a 

notice of issuance. Should the 

Commission make a final No Significant 

Hazards Consideration Determination, 

any hearing will take place after 

issuance. The Commission expects that 

the need to take this action will occur 

very infrequently. 

mstockstill on DSKH9S0YB1PROD with NOTICES